Abstract: The present application provides a displaying base plate and a displaying device, which relates to the technical field of displaying. The displaying device can ameliorate the problem of screen greening caused by electrostatic charges, thereby improving the effect of displaying. The displaying base plate includes an active area and a non-active area connected to the active area, the non-active area includes an edge region and a first-dam region, and the first-dam region is located between the active area and the edge region; the displaying base plate further includes: a substrate; an anti-static layer disposed on the substrate, wherein the anti-static layer is located at least within the edge region; and a driving unit and a touch unit that are disposed on the substrate, wherein the driving unit is located within the active area.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

Abstract: An in vitro rescue method for immature embryo of avocado includes: collecting immature avocado hybrid fruits, stripping immature zygotic embryos from the sterilized fruits; inducing maturation of zygotic embryos in different media selected according to the maturities of zygotic embryos; and avocado seed embryos growing to normal plants under light conditions after germination. Provided is a technology for the in vitro culture rescue of immature embryo of avocado, wherein the zygotic embryos at different developmental stages are induced to maturation under in vitro conditions, and after maturation, the seed embryos are induced to germinate and form healthy plants. The present invention can effectively improve the survival rate of hybrid avocado zygotic embryo, increase the success rate of hybrid avocado, rescue the hybrid offspring, reduce the loss of hybrid offspring, ensure the genetic integrity of hybrid group, and provide the key technology for hybrid breeding and genetic research of avocado.

Abstract: A system for providing exact communication delay guarantee of a request response for a distributed service, includes: a plurality of service provider nodes, a management node, and a plurality of proxy nodes; a set of users served by each service provider node constitutes a coverage area of the node; a communication delay between any user in the coverage area and the service provider node is less than a predetermined delay guarantee value; a physical network enables, according to division of the coverage areas of the service provider nodes, each user in the network to be located in a coverage area, and each user is served by at least one service provider node; and the coverage area includes a plurality of adjacent areas, and each service provider node has a plurality of adjacent nodes. In the system, each user can complete service request and response within a determined communication delay range.

Abstract: Provided is an in vitro rescue method for immature embryo of avocado, and the method includes: collecting immature avocado hybrid fruits, stripping immature zygotic embryos from the sterilized fruits; inducing maturation of zygotic embryos in different mediums selected according to the maturities of zygotic embryos; and avocado seed embryos growing to normal plants under light conditions after germination. Provided is a technology for the in vitro culture rescue of immature embryo of avocado, wherein the zygotic embryos at different developmental stages are induced to maturation under in vitro conditions, and after maturation, the seed embryos are induced to germinate and form healthy plants.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

Abstract: The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Abstract: The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Abstract: The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Abstract: The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Abstract: An apparatus for testing the gas permeability on the inward facing direction of a pre-impregnated resin matrix composite material layer includes a mold, a loading apparatus, a temperature control apparatus, a vacuuming apparatus, and a flow detecting element. A test specimen is laid flat inside the mold between airtight sealing elements that leave exposed two ends of the test specimen on the inward facing direction of the layer. An air inlet and an air outlet respectively are arranged on the mold and correspond to the two exposed ends of the test specimen. The inlet is connected to the flow detecting element, and the outlet is connected to the vacuuming apparatus. Air is forced to move in a vacuumed cavity along the inward facing direction of the layer. Testing of air permeability of pre-impregnated material in solidification technique is allowed via adjustments of pressure and temperature.

Abstract: An apparatus for testing the air permeability in the thickness direction of a resin matrix composite material layer includes a mold having a cavity and a covering plate, a loading apparatus, a temperature controlling apparatus, a vacuuming apparatus, and a flow detecting element. An air inlet is connected to the flow detecting element, and an air outlet is connected to the vacuuming apparatus. The covering plate has a through-hole with upper and lower ventilation pieces. The loading apparatus addresses the upper ventilation piece. A test specimen is laid flat between the ventilation pieces. Employment of the present invention allows for accurate testing of air permeability of pre-impregnated material in the thickness direction of the resin matrix composite material layer under different pressure and temperature conditions.

Abstract: The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.

Abstract: The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: An inductive output tube (IOT) operates in a frequency range above 1000 MHz. An output window may be provided to separate a vacuum portion of the IOT from an atmospheric pressure portion of the IOT, the output window being surrounded by a cooling air manifold, the manifold including an air input port and a plurality of apertures permitting cooling air to move from the port, through the manifold and into the atmospheric pressure portion of the IOT. The output cavity may include a liquid coolant input port; a lower circular coolant channel coupled to receive liquid coolant from the liquid coolant input port; a vertical coolant channel coupled to receive liquid coolant from the lower circular coolant channel; an upper circular coolant channel coupled to receive liquid coolant from the vertical coolant channel; and a liquid coolant exhaust port coupled to receive liquid coolant from the upper circular coolant channel.

Abstract: An inductive output tube (IOT) operates in a frequency range above 1000 MHz. An output window may be provided to separate a vacuum portion of the IOT from an atmospheric pressure portion of the IOT, the output window being surrounded by a cooling air manifold, the manifold including an air input port and a plurality of apertures permitting cooling air to move from the port, through the manifold and into the atmospheric pressure portion of the IOT. The output cavity may include a liquid coolant input port; a lower circular coolant channel coupled to receive liquid coolant from the liquid coolant input port; a vertical coolant channel coupled to receive liquid coolant from the lower circular coolant channel; an upper circular coolant channel coupled to receive liquid coolant from the vertical coolant channel; and a liquid coolant exhaust port coupled to receive liquid coolant from the upper circular coolant channel.

Abstract: An inductive output tube (IOT) operates in a frequency range above 1000 MHz. An output window may be provided to separate a vacuum portion of the IOT from an atmospheric pressure portion of the IOT, the output window being surrounded by a cooling air manifold, the manifold including an air input port and a plurality of apertures permitting cooling air to move from the port, through the manifold and into the atmospheric pressure portion of the IOT. The output cavity may include a liquid coolant input port; a lower circular coolant channel coupled to receive liquid coolant from the liquid coolant input port; a vertical coolant channel coupled to receive liquid coolant from the lower circular coolant channel; an upper circular coolant channel coupled to receive liquid coolant from the vertical coolant channel; and a liquid coolant exhaust port coupled to receive liquid coolant from the upper circular coolant channel.